CD11b, CD11c, CD18, and CD29 [3] , as well as MHC class II and CD23 [4] . In addition, IL-13 inhibits the production of pro-inflammatory mediators, including prostaglandins [5] , reactive oxygen and nitrogen intermediates [6, 7] , IL-1, IL-6, IL-8, tumor necrosis factor-(TNF-), and IL-12 [4] , by monocytes and macrophages, through a mechanism that involves the suppression of nuclear factor B (NF B) [8] . Furthermore, IL-13 has recently been shown to play an essential role in protective immunity against nematodes, but to have detrimental effects on immune responses against schistosomiasis and in asthma [9] [10] [11] .
IL-13 mediates its effects via a complex receptor system that includes the IL-4 receptor chain (IL-4R ) and two other cell surface proteins, IL-13R 1 and IL-13R 2 [12] [13] [14] [15] . IL-13R 1 binds IL-13 with low affinity. Co-expression of IL-13R 1 and IL-4R results in the formation of a high-affinity receptor signaling complex [13, 14, 16] , which is widely expressed on both lymphoid and nonlymphoid cells and can be activated by IL-4 [17] . In contrast to IL-13R 1, IL-13R 2 selectively binds IL-13 with high affinity but its contribution to signaling is unknown. The expression of IL-13R 2 transcripts is restricted to the spleen and brain and, in contrast to IL-13R 1, a soluble form of this receptor has been detected in mouse serum [18] . This has led to speculation that IL-13R 2 is a decoy receptor such as the IL-1 type II receptor [19] . Recently, IL-13R 2 was also shown to exist intracellularly, with large pools present in cultured monocytes, respiratory epithelial cells, primary respiratory epithelium, and primary human monocytes. This suggested that intracellular IL-13R 2 is not restricted to a few cell types but rather is more widespread [20] . Furthermore, this intracellular pool was rapidly mobilized to the cell surface after cells were treated with interferon-(IFN-). However, these observations were made in mammals and it remains to be seen if the paradigm for IL-13 and IL-13Rs extends to non-mammalian species.
To date, no evidence has been cited for the existence of a T2 cytokine paradigm in the chicken. However, recently, a chicken T2 cytokine gene cluster has been identified using a genomics approach based on the conservation of synteny [21] . Sequencing of bacterial artificial chromosomes (BACs) showed that the chicken genome encodes genes for the homologs of mammalian IL-3, IL-4, IL-5, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF) [21] . These sequences represent the first T2 cytokines found in nonmammalian species. In addition, mRNA and recombinant protein expression was demonstrated for four of these genes (IL-3, IL-4, IL-13, and GM-CSF) [21] .
Furthermore, recombinant chicken IL-4 (rchIL-4) and were both shown to cause chicken B cell proliferation when co-stimulated with CD154 (CD40 ligand) in the form of a fusion protein [21] . However, the receptors for these T2 cytokines have not been characterized in the chicken. Such receptor identification and investigation of biochemical and cellular properties requires the cloning of the gene that encodes the protein and the development of appropriate analytical tools. To this end, we have initiated the cloning of chicken IL-13R 2 and produced a specific monoclonal antibody (mAb) against it.
Materials and Methods

Animals and cell culture
Chicken tissue was obtained from partially inbred H-B15 White Leghorn chickens, originally kindly supplied by Dr. Vainio (Oulu University, Finland) , and bred in our animal facilities. They were provided with feed and chlorinated water ad libitum.
The monocytic chicken leukemia cell line, IN24 [22] and 5-μl aliquots of the products were separated on 1.5% agarose gels, which were stained with ethidium bromide (EtBr). The PCR products including the cDNA inserts were denatured with NaOH, transferred to nylon membranes, and then baked for 2 h at 70 ºC. Probes for hybridization were prepared from the subtracted cDNA and labeled using a digoxigenin (DIG) DNA labeling kit (Roche Diagnostics, Tokyo, Japan). The membranes were hybridized with DIG-labeled probes according to the supplier s instructions. Selected positive clones were sequenced with an automated ABI PRISM 3100 Genetic Analyzer (Applied Biosystems) using the ABI PRISM BigDye Terminator (Applied Biosystems).
Rapid amplification of cDNA ends (RACE) was performed to obtain the 3 and 5 ends of the chIL-13R 2 cDNA using the BD SMART RACE cDNA amplification kit (BD Biosciences Clontech), according to the manufacturer s instructions.
Phylogenetic analysis wae performed on the full-length amino acid sequences of the known IL-13 receptors and chicken IL-13R 2, using the ClustalX (http://bips.u-strasbg.fr/fr/Documentation/ClustalX/), and the default parameters were used. A phylogenetic tree was generated by the TreeView software (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html).
Reverse transcription-polymerase chain reaction (RT-PCR)
For expression analysis, 0.5 μg poly(A) + RNA, purified as described above, was reverse transcribed at 42 ºC using the SuperScript preamplification system (Invitrogen, Carlsbad, CA), in 20-μl reaction mixtures containing the oligo-(dT) [12] [13] [14] [15] [16] [17] [18] primer, as described by the manufacturer. cDNA was phenolchloroform extracted, ethanol precipitated, and resuspended in TE buffer ( 
Production of anti-chIL-13R 2 mAbs
Six-week-old female BALB/c mice were immunized intraperitoneally with 50 μg MBP-rchIL-13R 2 mixed with an equal volume of complete Freund s adjuvant. After three bi-weekly boosts with the same dose of immunogen in 0.1 ml PBS, mice with high serum titers of anti-rchIL-13R 2 antibodies were identified using an enzyme-linked immunosorbent assay (ELISA) and western blotting. These mice were injected intravenously with 50 μg MBP-rchIL-13R 2 in PBS and, three days later, their splenocytes were fused with SP2/0 Ag14 myeloma cells [23] using established methods [24] . Hybridomas secreting antirchIL-13R 2 antibodies were screened by ELISA, and cloned by limiting dilution.
The mouse immunoglobulin isotypes of the anti-rchIL-13R 2 mAbs were determined using a mouse monoclonal antibody isotyping kit (Amersham Biosciences, Piscataway, NJ).
ELISAs
ELISAs were carried out in NUNC-immunomodule microplates (Nalge The nucleotide sequence data reported in this paper have been filed in DDBJ/EMBL/GenBank under accession number AB243738.
Comparison of chicken and mammalian IL-13R 2 sequences
The deduced amino acid sequence of chIL-13R 2 was compared with that of human and mouse IL-13R 2 using the Pileup command (GCG program;
GCG sequence analysis software version 9.0, GCG Inc., USA). Alignment of the sequences, as shown in Fig. 2A , revealed that the putative chIL-13R 2 protein contained the ten cysteine residues which are conserved in mammalian IL-13R 2s. The chIL-13R 2 precursor protein shared 37.1% and 38.9% identity and 77.4% and 77.7% similarity to human and mouse IL-13R 2, respectively ( Fig. 2B) . Thus, as for other IL receptors, the degree of identity between chicken and mammalian IL-13R 2s was found to be low [26] [27] [28] .
To construct a tree depicting the relationship similarities between IL-13 2 and the other IL-13R members, a phylogenetic tree was derived using the ClustalX program and the neighbor joining method. Confidence values for the phylogenetic tree were generated by bootstrapping, based on 1000 resampling replicates. Our cloned chIL-13R 2 was shown to be a close relation of other IL-13R 2 (Fig. 3) .
Expression analysis
To determine the expression profile of chIL-13R 2, we performed semi-quantitative or real-time PCR with cDNAs prepared from IN24 cells stimulated in vitro and from various chicken tissues. RNA levels were quantified using real-time PCR and normalized to -actin expression levels in the same tissue. The level of expression of chIL-13R 2 mRNA was very low in untreated, control IN24 cells, but LPS treatment induced a gradual increase in its expression, which reached a maximum at 16 h (Fig. 4A) .
The normalized expression levels of chIL-13R 2 in various tissues, shown in Fig. 4B , are means from three independent experiments, expressed as tissue:kidney ratios, with the standard errors of the mean (SEM) shown. These real-time PCR experiments showed high levels of chIL-13R 2 expression in brain, liver, ovary, and testis.
Production and characterization of mAbs to rchIL-13R 2
We used a recombinant fusion protein, composed of the extracellular domain of chIL-13R 2 fused to MBP, as the immunogen to raise mAbs. The hybridomas were screened by ELISA for reactivity with MBP-chIL-13R 2 but not MBP, and this identified two hybridomas that were synthesizing anti-rchIL-13R 2 antibodies (Fig. 5 ), which were then cloned by limiting dilution. The single resulting mAb was an IgG1 immunoglobulin and was named HU13-1.
Western blotting The cDNA sequence we cloned encoded a 380 amino acid propeptide of chIL-13R 2. When this sequence was used in a BLAST search (http://www.ncbi.nih.gov/BLAST/), it was found to match a Gallus gallus mRNA (Accession number; XM_420209), which had been predicted by automated computational analysis from a genomic sequence. However, our cloned sequence covers only a small portion of the sequence obtained from this record (data not shown).
The chIL-13R 2 precursor protein was 37.1% and 38.9% identical to human and mouse IL-13R 2, respectively (Fig. 2B) . This low degree of identity between chicken and mammalian sequences has been seen with other chILs. In mammals, IL-13R 2 transcripts have been found in the brain, spleen, liver, thymus, and testis. Similarly, chIL-13R 2 transcripts have been found at high levels in the liver, testis, ovary, and brain [31, 32] . A distinctive aspect of this expression pattern is the high level of IL-13R 2 mRNA in both chicken and human testis [31] . Since nothing is so far known about the role of IL-13 in the germ line, the expression of this receptor in testis is particularly interesting.
The expression of chIL-13R 2 in IN24 cells was induced by the addition of LPS ( Fig. 4A and Fig. 7 ). In mammals, IL-13 suppresses the production of inflammatory cytokines by monocytes and macrophages [5] . Our results therefore suggested that pro-inflammatory stimulation of the chicken monocytic cell line, IN24, with LPS might prepare the cells for a response to IL-13. Furthermore, the mAb HU13-1 that we developed, reacted with both glycosylated and unglycosylated chIL-13R 2 ( Fig. 6B and Fig. 7 ). This will make it a particularly useful reagent for future studies of the biological activity of chIL-13 and its receptor.
Mammalian IL-13 has diverse functions, affecting a wide variety of cell types that are relevant to the pathogenesis of allergic disorders [2-4, 9, 10] . This multiplicity of activities highlights the potent immunoregulatory role of IL-13. In human B cells in particular, human IL-13 has similar effects to IL-4, promoting B-cell proliferation, and promoting class switching to IgG4 and IgE, in the presence of CD40/CD40 ligand co-stimulation [33] . In addition, IL-13 has been reported to activate mast cells and contribute to IgE priming of mast cells, given its role in promoting IgE synthesis [4] . However, chickens lack certain components of the IL-4 and IL-13 responses seen in mammals. For example, there is only a single chicken IgG equivalent, called IgY, and therefore no IgG sub-class switching occurs in chickens [34] . Chickens also lack IgE [34] . To study these intriguing differences between birds and mammals and why these kinds of differences occur during evolution, progress in the development of analytical tools is needed, to enable the characterization of chicken ILs and their receptors and increase the expertise available for further T2 interleukin research. The tree was constructed by the neighbor-joining method using the ClustalX and TreeView, and was bootstrapped 1000 times. 
